Naveen Pemmaraju Selected Research

Interleukin-3 Receptors (Interleukin 3 Receptor)

11/2021	Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.
1/2020	Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
10/2019	Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
1/2019	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
7/2014	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naveen Pemmaraju Research Topics

Disease

64	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2022 - 08/2011
63	Neoplasms (Cancer) 10/2022 - 10/2013
22	Primary Myelofibrosis (Myelosclerosis) 06/2022 - 09/2014
16	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2022 - 01/2015
15	Leukemia 01/2022 - 01/2015
13	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 07/2012
10	Hematologic Neoplasms (Hematological Malignancy) 05/2022 - 01/2017
10	Philadelphia Chromosome 01/2022 - 02/2015
9	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 12/2014
8	Thrombocytopenia (Thrombopenia) 01/2022 - 01/2018
7	Exanthema (Rash) 01/2021 - 11/2015
6	Fibrosis (Cirrhosis) 06/2022 - 07/2018
6	Infections 08/2021 - 11/2015
6	Residual Neoplasm 01/2021 - 12/2014
5	Anemia 01/2022 - 09/2014
5	Cytopenia 01/2022 - 10/2018
5	Capillary Leak Syndrome 12/2021 - 01/2019
5	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2021 - 10/2013
5	Pathologic Complete Response 07/2020 - 11/2015
4	Disease Progression 06/2022 - 01/2018
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2021 - 01/2019
4	Acute Promyelocytic Leukemia 01/2021 - 08/2013
4	Fatigue 01/2021 - 01/2017
4	Nausea 01/2020 - 02/2015
3	Hypoalbuminemia 10/2022 - 01/2019
3	Edema (Dropsy) 12/2021 - 01/2019
3	Blast Crisis (Blast Phase) 01/2021 - 11/2020
3	Hypertension (High Blood Pressure) 12/2020 - 11/2015
3	Pleural Effusion (Pleural Effusions) 01/2020 - 01/2014
3	Splenomegaly 01/2019 - 10/2014
3	Hemorrhage 12/2018 - 01/2015
3	Pancreatitis 12/2018 - 11/2015
2	Febrile Neutropenia 08/2021 - 01/2018
2	Neutropenia 01/2021 - 01/2021
2	COVID-19 01/2021 - 01/2021
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 01/2019
2	Hyperglycemia 01/2020 - 02/2015
2	Diarrhea 01/2020 - 01/2018

Drug/Important Bio-Agent (IBA)

26	venetoclaxIBA 11/2022 - 01/2017
15	ruxolitinibIBA 06/2022 - 03/2015
13	tagraxofuspIBA 10/2022 - 07/2014
13	Decitabine FDA Link 01/2022 - 09/2015
12	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2022 - 11/2013
11	Azacitidine (5 Azacytidine)FDA Link 01/2022 - 01/2015
10	Tyrosine Kinase InhibitorsIBA 01/2022 - 07/2012
7	Dasatinib (BMS 354825)FDA Link 11/2020 - 07/2012
6	Janus Kinase InhibitorsIBA 01/2022 - 01/2015
6	Hemoglobins (Hemoglobin)IBA 01/2022 - 09/2014
5	Transaminases (Aminotransferases)IBA 10/2022 - 02/2015
5	Pharmaceutical PreparationsIBA 01/2022 - 09/2015
5	Core Binding Factors (Core-Binding Factor)IBA 01/2022 - 04/2016
5	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 11/2021 - 07/2014
5	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 08/2021 - 11/2013
5	Clofarabine (Clolar)FDA Link 01/2021 - 11/2013
4	Cladribine FDA LinkGeneric 11/2022 - 01/2014
4	Rituximab (Mabthera)FDA Link 12/2021 - 02/2015
4	Vincristine (Oncovin)FDA LinkGeneric 12/2018 - 02/2015
4	ponatinibIBA 12/2018 - 09/2015
3	navitoclaxIBA 06/2022 - 01/2022
3	Biomarkers (Surrogate Marker)IBA 06/2022 - 01/2017
3	CytokinesIBA 06/2022 - 10/2019
3	fms-Like Tyrosine Kinase 3IBA 01/2022 - 07/2014
3	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2022 - 10/2019
3	InterferonsIBA 01/2022 - 12/2020
3	NivolumabIBA 12/2021 - 01/2019
3	fludarabineIBA 12/2021 - 11/2017
3	ibrutinibIBA 12/2021 - 01/2019
3	Alanine Transaminase (SGPT)IBA 08/2021 - 11/2015
3	Inotuzumab OzogamicinIBA 01/2021 - 01/2018
3	Lenalidomide (CC 5013)FDA Link 01/2021 - 01/2015
3	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 01/2019
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2019 - 11/2015
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 01/2017
3	BilirubinIBA 12/2018 - 02/2015
3	Prednisone (Sone)FDA LinkGeneric 12/2018 - 09/2014
3	Janus KinasesIBA 01/2017 - 01/2015
3	Imatinib Mesylate (Gleevec)FDA Link 11/2016 - 07/2012
3	nilotinib FDA Link 11/2016 - 07/2012
2	Alanine (L-Alanine)FDA Link 10/2022 - 10/2019
2	Reticulin (Reticular Fiber)IBA 01/2022 - 10/2018
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 12/2016
2	Immunotoxins (Immunotoxin)IBA 11/2021 - 01/2020
2	COVID-19 VaccinesIBA 05/2021 - 01/2021
2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2021 - 01/2019
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 01/2021
2	ArsenicIBA 01/2021 - 08/2013
2	Phosphotransferases (Kinase)IBA 12/2020 - 01/2017
2	Biological ProductsIBA 12/2020 - 09/2013
2	nelarabine (506U78)FDA Link 11/2020 - 01/2018
2	ofatumumab FDA Link 07/2020 - 01/2020
2	midostaurinIBA 11/2019 - 08/2019
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 09/2019 - 08/2013

Therapy/Procedure

74	Therapeutics 10/2022 - 07/2012
30	Drug Therapy (Chemotherapy) 05/2022 - 08/2011
6	Immunotherapy 05/2022 - 01/2017
4	Induction Chemotherapy 01/2022 - 01/2016
4	Stem Cell Transplantation 01/2021 - 05/2015
3	Drug Tapering 01/2020 - 01/2018
2	Cell Transplantation 01/2022 - 03/2019
2	Salvage Therapy 01/2021 - 06/2013